GLIMEPIRIDE 3mg. IP + METFORMIN 500mg. IP

An anti-diabetic class of medicine that is used in the management of type 2 diabetes mellitus. An effective therapeutic choice for patients inadequately controlled on sulfonylurea or Metformin alone. (Anil Pareek, 2013) The preferred choice in hypertensive patients with diabetes for optimal blood glucose control. (Rakesh Kumar Sahay, 2020) A suitable combinational drug for early as well as long-standing diabetes. (Rakesh Kumar Sahay, 2020) Reduces pill burden and provides effective glycemic control in type 2 diabetic patients. (Sudhir Tripathi, 2019) A potential agent that provides greater adherence to therapy and improves glycemic control. (Sudhir Tripathi, 2019) Stimulates pancreatic β cells to release insulin and reduces blood sugar. (Abdul Basit M. R., 2012) An effective drug that controls hyperglycemia in people with T2DM. (Sudhir Tripathi, 2019) Effectively reduces fasting plasma glucose, post-prandial glucose, and glycosylated hemoglobin levels. (Abdul Basit, 2012) Significantly more effective in controlling blood glucose levels in type 2 diabetic patients inadequately controlled by metformin alone. (G Charpentier, 2001) A potential agent that achieves good glycemic control with a better tolerability profile. (Anil Pareek, 2013) A preferential option for most type 2 diabetes mellitus patients who have not achieved adequate control with monotherapy. (JM. Amate, 2015) An effective and well-tolerated antidiabetic drug that provides an important treatment option for managing type 2 diabetes. (Massi-Benedetti, 2003)